Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis (SHUM)
Primary Purpose
Respiratory Failure, Volume Overload, Hypernatremia
Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Supplemental metolazone diuresis
Placebo Comparator: Control-- furosemide (lasix) only
Sponsored by
About this trial
This is an interventional treatment trial for Respiratory Failure
Eligibility Criteria
Inclusion Criteria:
- ICU patients who are intubated and slated for diuresis in anticipation of extubation.
- Patients must be hypernatremic (Na > 140 mEq/L) at the time diuresis is initiated or become hypernatremic over the course of receiving loop diuretics in anticipation of extubation.
- GFR > 30 ml/min [as calculated by the MedCalc MDRD formula {GFR = 170 x PCr - 0.999 x Age - 0.176 x BUN - 0.170 x Albumin0.318 x 0.762 (for women) x 1.180 (for blacks)} ]
Exclusion Criteria:
- History of allergy to furosemide or any thiazide diuretic
- Inability to place enteral access
- Moribund status
Sites / Locations
- Oregon Health Sciences University
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Control-- furosemide (lasix) only
Study Arm
Arm Description
Control arm receives standard of care diuresis with furosemide(lasix)only. The treatment team will decide the dosing of furosemide (lasix). No actual placebo is administered.
Study arm receives evolving standard of care diuresis with furosemide and metolazone.
Outcomes
Primary Outcome Measures
Fluid balance
Differences in fluid balance (total net liters negative from the time diuresis is initiated) between the study group and control group at the following intervals: 24, 36, 48, and 72 hours after either protocol is initiated.
Secondary Outcome Measures
Serum sodium
Number patients whose Na remains below 145 (meq/L) during the period of diuresis; versus the number of patients whose sodium exceeds 145 (meq/L) and require free water replacement.
Hyponatremia
Number of patients who develop hyponatremia (Na < 136 meq/L)
Time to extubation
Time in hours from initiation of protocol to extubation (difference between study group and control group
Acute Kidney Injury
Number of patients who develop acute kidney injury (increase in creatinine by more than 25%)
Full Information
NCT ID
NCT01617798
First Posted
June 1, 2012
Last Updated
June 4, 2019
Sponsor
Oregon Health and Science University
1. Study Identification
Unique Protocol Identification Number
NCT01617798
Brief Title
Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis
Acronym
SHUM
Official Title
Stop Hypernatremia, Use Metolazone for Aggressive, Controlled, Effective Diuresis
Study Type
Interventional
2. Study Status
Record Verification Date
June 2019
Overall Recruitment Status
Withdrawn
Why Stopped
Investigator departed organization
Study Start Date
June 2012 (undefined)
Primary Completion Date
June 2013 (Anticipated)
Study Completion Date
June 2013 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oregon Health and Science University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Patients who are on mechanical ventilation in an intensive care unit often require diursis as part of their pre-extubation regimen. The drug of choice for diuresis has traditionally been furosemide. However, this drug cause hypernatremia (a rise in serum sodium) in a significant proportion of patients. Hypernatremia is traditionally treated by providing free water supplementation to the patient. This strategy creates a vicious and unproductive cycle of giving free water, and then diuresing it off. We propose a strategy for breaking this cycle by using a second diuretic-- metolazone-- which has a tendency to rid the body of more sodium, thereby minimizing hypernatremia.
Detailed Description
Mechanical ventilation is a mainstay of Intensive Care. Weaning from mechanical ventilation remains a significant issue in Intensive Care Unit (ICU) care worldwide. It is well established that a strategy of diuresis with negative fluid balance shortens the duration of mechanical ventilation in both acute lung injury and cardiogenic pulmonary edema patients. Despite publication of at least one formalized but complex evidence-based conservative fluid strategy, there is no practical, uniformly implemented protocol for setting or achieving volume status targets. The default approach at many hospitals involves using ad hoc doses (either intermittent or continuous) of a loop diuretic (usually furosemide) with instructions to monitor fluid balance and follow electrolytes in an attempt to reach arbitrary target volume diuresis. Moreover, there are barriers to achieving any particular target, including pre-existing renal failure/diuretic resistance, diuretic-induced creatinine elevation, acquired diuretic resistance, hypotension from volume loss, and electrolyte derangements including hypokalemia and hypernatremia. Strategies exist for preventing or treating the above complications but there is presently no accepted standard for preventing or treating diuretic-induced hypernatremia. In fact, the standard current intervention is to replace the free water deficit that may be induced by the loop diuretic, while simultaneously perpetuating the free water deficit by continuing to administer the causative loop diuretic. This approach is circular and does not effectuate the desired negative fluid balance. We will address the lack of an accepted prevention strategy using a randomized controlled clinical trial in ICU patients with the following specific aims:
Conduct a randomized, pilot trial of standard versus metolazone supplemented diuresis in ICU patients with the primary outcome of improved negative fluid balance.
Assess secondary outcomes including time to extubation, exacerbation of renal failure, and incidence of electrolyte derrangements in the treatment and control arms.
Track whether initial hypernatremia within the control group is a risk factor for poor diuresis with furosemide, and whether it delays extubation.
The anticipated benefits of our proposed intervention involve fundamental ICU and patient care quality measures: avoiding the pitfalls of hypernatremia and diuretic resistance should lead to more effective diuresis, which should in turn lead to a more negative fluid balance, earlier liberation from the ventilator, and a shorter length of stay in the ICU.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Failure, Volume Overload, Hypernatremia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Control-- furosemide (lasix) only
Arm Type
Placebo Comparator
Arm Description
Control arm receives standard of care diuresis with furosemide(lasix)only. The treatment team will decide the dosing of furosemide (lasix).
No actual placebo is administered.
Arm Title
Study Arm
Arm Type
Active Comparator
Arm Description
Study arm receives evolving standard of care diuresis with furosemide and metolazone.
Intervention Type
Drug
Intervention Name(s)
Supplemental metolazone diuresis
Other Intervention Name(s)
furosemide, lasix
Intervention Description
Patients in the Study Arm will receive supplemental diuresis with metolazone 2.5 mg per dobhoff tube twice daily, in addition to furosemide as the primary team sees fit.
Intervention Type
Drug
Intervention Name(s)
Placebo Comparator: Control-- furosemide (lasix) only
Other Intervention Name(s)
furosemide, lasix, metolazone
Intervention Description
Control arm will receive furosemide as monotherapy for diuresis
Primary Outcome Measure Information:
Title
Fluid balance
Description
Differences in fluid balance (total net liters negative from the time diuresis is initiated) between the study group and control group at the following intervals: 24, 36, 48, and 72 hours after either protocol is initiated.
Time Frame
24, 36, 48, and 72 hours after either protocol is initiated
Secondary Outcome Measure Information:
Title
Serum sodium
Description
Number patients whose Na remains below 145 (meq/L) during the period of diuresis; versus the number of patients whose sodium exceeds 145 (meq/L) and require free water replacement.
Time Frame
Continuous for 72 hours
Title
Hyponatremia
Description
Number of patients who develop hyponatremia (Na < 136 meq/L)
Time Frame
Continuous for up to 72 hours
Title
Time to extubation
Description
Time in hours from initiation of protocol to extubation (difference between study group and control group
Time Frame
Unitl the patient is actually extubated, undergoes tracheostomy, or expires.
Title
Acute Kidney Injury
Description
Number of patients who develop acute kidney injury (increase in creatinine by more than 25%)
Time Frame
Continuous for the first 72 hours
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
ICU patients who are intubated and slated for diuresis in anticipation of extubation.
Patients must be hypernatremic (Na > 140 mEq/L) at the time diuresis is initiated or become hypernatremic over the course of receiving loop diuretics in anticipation of extubation.
GFR > 30 ml/min [as calculated by the MedCalc MDRD formula {GFR = 170 x PCr - 0.999 x Age - 0.176 x BUN - 0.170 x Albumin0.318 x 0.762 (for women) x 1.180 (for blacks)} ]
Exclusion Criteria:
History of allergy to furosemide or any thiazide diuretic
Inability to place enteral access
Moribund status
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Steiger, JD MD
Organizational Affiliation
Oregon Health and Science University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dan Hagg, MS MD
Organizational Affiliation
Oregon Health and Science University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Oregon Health Sciences University
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis
We'll reach out to this number within 24 hrs